EDIT saw its Momentum Indicator move below the 0 level on October 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 78 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.501) is normal, around the industry mean (3.043). P/E Ratio (-3.636) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 49 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 31 of 52 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +2.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 176 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RPRX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.162) is normal, around the industry mean (3.043). P/E Ratio (34.150) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.015) settles around the average of (133.535) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The RSI Indicator for VRTX moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 12 of the 14 cases the stock moved higher. This puts the odds of a move higher at 86%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VRTX as a result. In 59 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for VRTX just turned positive on October 20, 2026. Looking at past instances where VRTX's MACD turned positive, the stock continued to rise in 38 of 60 cases over the following month. The odds of a continued upward trend are 63%.
VRTX moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 237 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
VRTX broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRTX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 16 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 24 (best 1 - 100 worst), indicating outstanding price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.558) is normal, around the industry mean (3.043). P/E Ratio (30.267) is within average values for comparable stocks, (-1.361). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (438.009).
EDIT | RPRX | VRTX | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 34 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 91 Overvalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 23 | 16 | |
SMR RATING 1..100 | 99 | 97 | 41 | |
PRICE GROWTH RATING 1..100 | 74 | 38 | 24 | |
P/E GROWTH RATING 1..100 | 23 | 4 | 39 | |
SEASONALITY SCORE 1..100 | 50 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EDIT's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for RPRX (91) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for VRTX (92) in the Biotechnology industry. This means that EDIT's stock grew somewhat faster than RPRX’s and somewhat faster than VRTX’s over the last 12 months.
VRTX's Profit vs Risk Rating (16) in the Biotechnology industry is in the same range as RPRX (23) in the Pharmaceuticals Major industry, and is significantly better than the same rating for EDIT (100) in the Biotechnology industry. This means that VRTX's stock grew similarly to RPRX’s and significantly faster than EDIT’s over the last 12 months.
VRTX's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for EDIT (99) in the Biotechnology industry. This means that VRTX's stock grew somewhat faster than RPRX’s and somewhat faster than EDIT’s over the last 12 months.
VRTX's Price Growth Rating (24) in the Biotechnology industry is in the same range as RPRX (38) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for EDIT (74) in the Biotechnology industry. This means that VRTX's stock grew similarly to RPRX’s and somewhat faster than EDIT’s over the last 12 months.
RPRX's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as EDIT (23) in the Biotechnology industry, and is somewhat better than the same rating for VRTX (39) in the Biotechnology industry. This means that RPRX's stock grew similarly to EDIT’s and somewhat faster than VRTX’s over the last 12 months.
| EDIT | RPRX | VRTX | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 66% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 56% | 1 day ago 65% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 53% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 60% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 57% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 59% | 1 day ago 68% |
| Advances ODDS (%) | 4 days ago 80% | 1 day ago 56% | 2 days ago 65% |
| Declines ODDS (%) | 1 day ago 90% | 18 days ago 49% | 11 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 51% | 1 day ago 62% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 69% | 1 day ago 47% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s), and VRTX’s FA Score reflects 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s), and VRTX’s TA Score reflects 5 bullish TA indicator(s).
EDIT (@Biotechnology) experienced а +2.13% price change this week, while RPRX (@Biotechnology) price change was +4.76% , and VRTX (@Biotechnology) price fluctuated +4.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
EDIT is expected to report earnings on Nov 09, 2026.
RPRX is expected to report earnings on Nov 04, 2026.
VRTX is expected to report earnings on Nov 02, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | +0.17% | ||
| AXON - RPRX | 48% Loosely correlated | +1.39% | ||
| INCY - RPRX | 47% Loosely correlated | -1.04% | ||
| VRTX - RPRX | 45% Loosely correlated | -2.10% | ||
| RIGL - RPRX | 40% Loosely correlated | -1.49% | ||
| EXEL - RPRX | 39% Loosely correlated | -1.19% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TMB | 24.92 | N/A | N/A |
| Thornburg Multi Sector Bond ETF (TMB) | |||
| VBCC | 74.39 | -0.06 | -0.07% |
| Vanguard Target Maturity 2029 Corporate Bond ETF (VBCC) | |||
| ENS.X | 5.473698 | -0.023710 | -0.43% |
| Ethereum Name Service cryptocurrency | |||
| AAOG | 0.83 | -0.02 | -2.14% |
| Leverage Shares 2X Long AAOI Daily ETF (AAOG) | |||
| XNO.X | 0.328824 | -0.007539 | -2.24% |
| Nano cryptocurrency | |||